Dr. John Cush RheumNow
7 years 7 months ago
Study of 21,016 SLE patients from Korean Health Claims databases shows SLE patients have a higher risk of cancer than controls (OR 1.44; 95% CI 1.33–1.56) with highre rates of cervical, thyroid, ovarian, oral cancer, lymphoma, leukemia, & multiple myeloma https://t.co/NKR9i4ccfU
Dr. John Cush RheumNow
7 years 7 months ago
Time to register for this weeks RheumNow Live. Free online streaming video - 16 hrs of Innovative lectures and Q&A Panels from friday afternoon 3/22, till noon Sunday 3/24. Register for FREE at https://t.co/wIgS5rq4UE
A Lancet study has shown that adding cyclosporin to intravenous immunoglobulin (IVIG) Kawasaki disease patients, who were predicted to be resistant to IVIG, was both safe and effective in averting severe coronary artery outcomes.
Dr. John Cush RheumNow
7 years 7 months ago
QD Clinic - When To Stop MTX- Should/Can a Patient ever stop MTX? | RheumNow
https://t.co/z0Dhwdbr3Q
Dr. John Cush RheumNow
7 years 7 months ago
European Commission Approves MabThera (rituximab) for use in Pemphigus, US FDA approved it in 6/18; RTX is now approved in 4 autoimmune disorders in the US & Europe (RA, GPA, MPA, Pemphigus) - Not approved for use in children https://t.co/dJJfPdXuWQ(rituxim/364143/index.html
QD Clinic - When To Stop MTX
Should/Can a Patient ever stop MTX?
Dr. John Cush RheumNow
7 years 7 months ago
Nice comprehensive full read review of the Diagnosis and Management of Paget's Disease of Bone in Adults: A Clinical Guideline from the JBMR. https://t.co/Eh9xfPJ2B0
Dr. John Cush RheumNow
7 years 7 months ago
Vedolizumab superior to adalimumab in clinical remission (31 vs 22%) and mucosal healing(40 vs 28%) at week 52 when given to383 patients with moderate to severely active ulcerative colitis. Data presented at European Crohn’s and Colitis Congress. https://t.co/dXrEkzhnKh
Ironwood Pharmaceuticals discontinued the marketing and sales of both lesinurad (Zurampic) the combination drug of lesinurad and allopurinol (Duzallo) in the United States effective February 1, 2019. In addition the Duzallo and Zurampic Patient Savings Program were also discontinued on December 31, 2018.
The company stated that this was a financial decision unrelated to the efficacy or safety of lesinurad.
In patients with rheumatoid arthritis (RA), there was no increased risk for malignancy development seen with newly initiated tocilizumab (Actemra) treatment, an analysis of three U.S. insurance claim databases found.
Dr. John Cush RheumNow
7 years 7 months ago
Daily noninvasive ultrasound (US) stimulation of the spleen significantly reduces disease severity in a murine model of inflammatory arthritis. Results mediated via T & B cell effects as T/B deficient mice did not improve with splenic US. https://t.co/dSlYWEgplR
Dr. John Cush RheumNow
7 years 7 months ago
The Weekly RheumNow Podcast is up! https://t.co/qA4wADpPN8 or listen to it on iTunes or SoundCloud https://t.co/mZ3y0yvwA3
Courtesy of the Canadian Rheumatology Association (CRA) website, here are consensus guidelines on medical cannabis use.
Rheumatology patients experience prevalent pain that is only modestly controlled with current treatment strategies.
Dr. Jack Cush reviews this week's news and highlights from RheumNow.com.
